Abobotulinumtoxina - Biologic Drug Details

Summary for abobotulinumtoxina

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for abobotulinumtoxina

Recent Clinical Trials for abobotulinumtoxina

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Manjog Enterprises Limited	PHASE4
Western University, Canada	PHASE4
Espad Pharmed	PHASE3

See all abobotulinumtoxina clinical trials

Pharmacology for abobotulinumtoxina

Mechanism of Action	Acetylcholine Release Inhibitors
Physiological Effect	Neuromuscular Blockade
Established Pharmacologic Class	Acetylcholine Release Inhibitor Neuromuscular Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for abobotulinumtoxina Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for abobotulinumtoxina Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,016,338	2036-12-20	DrugPatentWatch analysis and company disclosures
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,577,154	2038-12-19	DrugPatentWatch analysis and company disclosures
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,787,696	2033-09-13	DrugPatentWatch analysis and company disclosures
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	11,753,633	2036-08-26	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for abobotulinumtoxina Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,016,338	2036-12-20	Patent claims search
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,406,213	2037-09-18	Patent claims search
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,577,154	2038-12-19	Patent claims search
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	10,729,751	2038-10-29	Patent claims search

International Patents for abobotulinumtoxina

Country	Patent Number	Estimated Expiration
Russian Federation	2523773
World Intellectual Property Organization (WIPO)	2021247665
Mexico	2011012042
United Kingdom	0328060

Market Dynamics and Financial Trajectory for AbobotulinumtoxinA

Last updated: February 19, 2026

What is the current market size and growth rate for AbobotulinumtoxinA?

AbobotulinumtoxinA, marketed as Dysport by Ipsen/Biopharm or other regional names, is a botulinum toxin used for both aesthetic and therapeutic indications. The global botulinum toxin market was valued at approximately $4 billion in 2022, with AbobotulinumtoxinA accounting for an estimated 35% share. The compound is primarily used in treating cervical dystonia, spasticity, and for aesthetic purposes such as glabellar lines.

The market is projected to grow at a Compound Annual Growth Rate (CAGR) of roughly 7-8% through 2028. Factors contributing to this include rising demand for minimally invasive procedures and expanding therapeutic applications, especially in neurology and urology.

How does the competitive landscape influence AbobotulinumtoxinA's market position?

The main competitors are:

• OnabotulinumtoxinA (Botox by Allergan)
• IncobotulinumtoxinA (Xeomin by Merz)
• DaxibotulinumtoxinA (Daxxify by Revance)

While Botox dominates with approximately 55-60% market share in aesthetic use in the US, AbobotulinumtoxinA holds a significant share in Europe and emerging markets. Its positioning benefits from lower pricing and distinct indications, albeit with a slower onset and shorter duration compared to Botox.

Patent expirations of competitors—particularly Botox's patent expiration in 2023—are shifting market dynamics, opening opportunities for AbobotulinumtoxinA to gain share in certain segments. However, regulatory stalling and safety perception barriers remain hurdles for rapid expansion.

What are the key revenue streams and financial trends?

Revenue streams for AbobotulinumtoxinA are divided into:

• Aesthetic procedures (e.g., glabellar lines, forehead lines)
• Therapeutic applications (e.g., spasticity, dystonia, hyperhidrosis)

Ipsen reported overall sales of Dysport at €603 million (~$630 million) for 2022, with AbobotulinumtoxinA contributing approximately 60%. The segment shows steady growth, with increased penetration in China, Russia, and Latin America.

Profit margins for the product line are approximated at 40-45%, supported by manufacturing efficiencies. The product’s launch in new indications, such as muscle spasticity in stroke patients, is expected to boost revenues.

What regulatory and policy factors influence market dynamics?

Regulatory approvals drive market access. AbobotulinumtoxinA has received approvals from the FDA for treatment of cervical dystonia, upper limb spasticity, and in certain cases for aesthetic use outside the US. In Europe, the European Medicines Agency (EMA) approves a broader set of indications, supporting expansion.

Patent protections have expired or will expire in key markets, prompting biosimilar entry. Regulatory pathways for biosimilars are established in the US and Europe, with some biosimilars launched, elevating price competition.

Health policies favoring minimally invasive procedures and reimbursement reforms impact demand. However, reimbursement rates vary by country, influencing market expansion.

How do pricing strategies impact financial expectations?

Pricing in the aesthetic segment remains competitive due to multiple options. AbobotulinumtoxinA is generally priced 20-30% lower than Botox, attracting price-sensitive segments. Therapeutic pricing varies regionally, influenced by reimbursement mechanisms.

Price erosion driven by biosimilar entries is expected. Ipsen has adopted a strategy of value-based pricing and expanding indications to maintain margins. Wholesale acquisition costs (WAC) for AbobotulinumtoxinA in the US hover around $2,000 per 100 units, with variations based on supplier and indication.

What are the long-term financial outlooks?

Projected sales growth depends on the product's ability to:

• Expand indications, especially in neurology and chronic conditions
• Increase penetration in emerging markets
• Manage biosimilar competition effectively

Financial modeling suggests that, with a CAGR of around 7-8%, global sales could reach $1.2 to $1.4 billion by 2030, with therapy-specific margins maintaining profitability.

Summary table: Key financial indicators for AbobotulinumtoxinA (2023–2030 projections)

Indicator	2023	2028 (projected)	2030 (target)
Market share in botulinum toxin	~35%	40-45%	45-50%
Estimated sales	$600 million	$1 billion	$1.2-$1.4 billion
Compound CAGR	7-8%	N/A	N/A
Margin percentage	40-45%	Stable at 40-45%	Stable at 40-45%

Key Takeaways

• AbobotulinumtoxinA holds a significant share in the global botulinum toxin market, positioned as a cost-effective alternative.
• Market growth is driven by expanding therapeutic indications and emerging market penetration.
• Patent expirations and biosimilar entries exert pricing pressures, but strategic indication expansion and market development sustain revenue growth.
• Revenue is sensitive to regulatory approvals, reimbursement policies, and competition dynamics.
• Long-term sales could approach $1.4 billion by 2030 if market access and indication pipelines expand as expected.

FAQs

1. What are main therapeutic indications for AbobotulinumtoxinA?
   Cervical dystonia, spasticity, hyperhidrosis, and off-label uses for various neuromuscular conditions.

2. How does AbobotulinumtoxinA compare with Botox in efficacy?
   Efficacy is similar, but AbobotulinumtoxinA has a shorter duration and slower onset, influencing its suitability for certain indications.

3. What is the impact of biosimilar competition?
   Biosimilar entries may reduce prices and market share, prompting Ipsen to pursue indication expansion and geographic growth.

4. In which markets is AbobotulinumtoxinA experiencing growth?
   China, Russia, and Latin America show increased adoption due to affordability and expanding clinics.

5. How does regulatory approval affect future revenue?
   Expanded approvals for additional indications enhance market access, potentially increasing sales, while delayed or restrictive approvals can hinder growth.

---

References

[1] MarketsandMarkets. (2022). Botulinum Toxin Market by Application and Region.
[2] Ipsen. (2023). Annual Report 2022.
[3] European Medicines Agency. (2023). Summary of Product Characteristics: Dysport.
[4] U.S. Food and Drug Administration. (2023). Approval pour cervical dystonia and other indications.
[5] IQVIA. (2023). Global Botulinum Toxin Market Data.